and anorexia. One or two days later, blisters appear in the mouth, and rashes develop on the cheeks, gums and tongue. 4, 5 In recent years, HFMD has become more common in Asia-Pacific region, and especially in China. 6 A report by the Ministry of Health of China in 2010 documented that there were over one million DOI: 10.1515/ii-2017-0048 HFMD cases annually and more than 2 000 HFMDassociated deaths in China over the past 3 years. 7 Commonly, HFMD is mild and self-limiting, with relief of symptoms within 7-10 days, but viruses can be detected in the stool for weeks after the symptoms dissipate. 4, 8 There are no specific treatments for HFMD at present. The most common treatment is to relieve symptoms by supportive therapy and the application of antivirals, antibiotics and immunopotentiators. 5, 8 According to the guidelines issued by the Ministry of Health of China, 9 HFMD should be paid enough attention during the first five days in case it progress into severe conditions without immediate and effective intervention. Traditional Chinese medicine (TCM) was highly recommended by Ministry of Health of China for HFMD treatment. 9 Previous reports showed that treatment with TCM could significantly alleviate disease symptoms. 10, 11 Reduning and Xiyanping injections have been widely used in clinical practice to alleviate the fever and inflammation associated with HFMD. 12, 13 In present study, we conducted a well designed prospective clinical trial with a sufficient sample size to observe the efficacy and safety of TCM in conjunction with conventional therapy in treating HFMD.
PATIENTS AND METHODS

Study design
A p r o s p e c t i v e , r a n d o m i z e d , c o n t r o l l e d a n d multicenter trial was conducted during the HFMD epidemic at 14 medical centers in China. A total of 452 eligible children with common HFMD were recruited. The study was conducted in accordance with the Declaration of Helsinki, approved by local ethics committees and institutional review boards as appropriate. All patients and their guardians agreed and provided signed written informed consent forms before enrollment.
Patient enrollment
The diagnosis of common HFMD was established according to the guidelines for the diagnosis and treatment of HFMD issued by the Ministry of Health of China in 2010. 9 In addition, the following inclusion criteria were considered: aging 1-14 years old; no more than 48 hours after the occurrence of rash/herpes or fever symptoms.
Patients were excluded if they had other primary diseases such as congenital heart disease, chronic hepatitis, acute or chronic nephritis, and blood diseases; with a history of allergy to herbal medicine; participating in other clinical studies on HFMD; with any condition that could interfere with the evaluation of our study's objectives.
In addition, enterovirus isolation and identification were performed in Clinical Test Center of Beijing Youan Hospital. Human EV71, Coxsackievirus A16 and enterovirus general type nucleotide acid detection kit were applied for the identification. During the recruitment phase, this notification was collated by assistants at each collaborating practice and reviewed by the trial investigators to exclude children who did not fulfill the eligibility criteria.
Sample size and randomization
Given that the previous clinical trials on evaluating Chinese herbal medicines in the treatment of HFMD were so limited, mostly due to small size of samples and no formal power calculations were obtained, and we therefore designed this study to recruit more samples (n = 452) from multiple centers in China to ensure a sufficient sample size and draw objective conclusions. 13, 14 Participants were randomly assigned into two treatment groups using a web-based randomization system provided by China Academy of Chinese Medical Sciences, which adopted the computer telephone integration technology to integrate computer, internet and telecom. 13 After eligibility had been determined and consent had been obtained, the trial identification number, date of birth and trial center name were entered into this randomization system. The random number list was generated by a statistician who was not involved in data collection or analysis. The researcher immediately informed a coordinator at each center who was blinded to the participants' characteristics to assign the participants to treatment. The participants were also blinded to the treatment assignment. 13 Randomization was stratified by 14 medical centers, locating in Beijing, Anhui Province, Hunan Province, Henan Province, Guangdong Province, Guangxi Province, Fujian Province, Hebei Province and Jiangxi Province in China, which were selected to ensure broad geographic spread and representation of HFMD. 13 
Drug administration
Western medicine therapy was administered to patients in both two groups according to the guidelines for the diagnosis and treatment of HFMD (China, 2010). 9 In the integrated TCM and Western medicine therapy group, patients received Western medicine therapy combined with Reduning or Xiyanping injections. Reduning injection that consists of the following three herbs, qinghao (Herba artemisia annua), jinyinhua (Lonicera japonica Thunb), and zhizi (Gardenia jasminoides Ellis), is manufactured by GMP-certified Jiangsu Kangyuan Pharmaceutical, Inc., China. Xiyanping injection was light yellow to orange clear liquid, which is composed of total andrographolide sulfonate (manufactured by GMP-certificated Jiangxi Qingfeng Pharmaceutical, Inc., China). The criteria for the quality of Reduning or Xiyanping injections were in accordance with the Chinese pharmacopoeia (2005). 15 Reduning injection was administered to patients at 0.5 ml·kg -1 ·d -1 by intravenous infusion (in 5% dextrose) whereas andrographolide sulfonate was administered 5-10 mg·kg -1 ·d -1 for intravenous infusion (in 5% dextrose).
Patients in two groups were followed-up every day during treatment period and for 3 days in posttreatment period.
Assessment of clinical outcomes
During the course of study, the presence of HFMD symptoms and drug-associated side effects were recorded routinely. Primary clinical outcome was the incidence rate of rash/herpes disappearance within 5 days, while secondary outcomes included the incidence rate for fever, cough, runny nose, lethargy and weakness, agitation or irritability, and vomiting clearance within 5 days. The intervention-related side effects were also recorded.
Statistical analysis
Categorical variables were expressed as percentages and analyzed by chi-squared test. Continuous variables were analyzed by unpaired t-test. All tests were in two-tailed, and P values less than 0.05 was considered statistically significant. All statistical procedures were performed with SAS software (version 9.2; SAS Institute, Inc., Cary, NC, USA).
RESULTS
Participants' characteristics
Total of 466 participants from 14 medical centers in 8 provinces in China were recruited, 14 of whom were excluded due to no informed consents or not meeting inclusion criteria. In total, 452 participants were randomly assigned into two groups and included in a full analysis set (FAS).
The baseline demographic characteristics including gender, age, height, body weight and body temperature were similar between the two groups (Table 1) , with no statistical differences, and thus were comparable.
Clinical outcomes
The study showed TCM and Western medicine combined therapy could effectively alleviate HFMDassociated symptoms compared with Western medicine therapy alone. With respects to the primary clinical outcome, the incidence rate of rash/herpes disappearance within 5 days was 45.5% (100/220) in Western medicine therapy group, and 67.2% (156/232) in TCM and Western medicine combined therapy group, with significant difference (P < 0.001) ( Table 2 ). As for secondary clinical outcomes, TCM remarkably increased the incidence rate of fever, cough, lethargy and weakness, agitation or irritability disappearance within 5 days, which was 56.4% in the Western medicine therapy group and 71.4% in the TCM and Western medicine combined therapy group ( P = 0.001) ( Table 2 ).
In addition, Reduning or Xiyanping injections were both well tolerated. During the treatment, there were no drug-related side effects or adverse events observed in both groups.
DISCUSSION
Several clinical trials have assessed the efficacy and safety of TCM in treatment of HFMD, 12,14 also with certain limitations. First, most trials were restricted to a small sample size, which yielded bias and did not reflect the general population of patients. Second, the findings of these trials were mostly reported in Chinese journals without translation into English and thus cannot be well recognized around the world. This is one of the first prospective, randomized and controlled trials to evaluate the efficacy and safety of herbal medicines, such as Reduning or Xiyanping injections, in the treatment of common HFMD. In conjunction with Western medicine, administration of TCM (Reduning or Xiyanping injections) significantly increased the rate of rash/herpes disappearance within 5 days after the onset of illness as well as relieving other symptoms such as fever, cough, fatigue and irritation related to HFMD. Based on these clinical observations, we may suggest that TCM in the form of Reduning or Xiyanping injections is a complementary medication in HFMD treatment.
Reduning injection, one of the famous traditional Chinese preparations, consists of three herbs, Herba artemisia annua, Lonicera japonica Thunb, and Gardenia jasminoides Ellis. 12 The mechanism of Reduning injection in treatment of HFMD is yet to be elucidated. It has been reported that artemisia annua has numerous biological functions such as antimicrobial and antiparasitic properties. 16 Lonicera japonica Thunb and Gardenia jasminoides are known for their abilities to remove heat and toxic materials and to relieve inflammation. 17 These herbs are widely used as important components in TCM formulas in clinical settings. It is speculated that the synergy of the three individual herbs is responsible for the therapeutic efficacy of Reduning injection in the treatment of common HFMD.
The main bioactive compound in Xiyanping injection is herb-derived compound andrographolide sulfonate, which is obtained from a popular Chinese herb andrographis paniculata (Burm) Nees. 13 Andrographolide sulfonate is known to have many types of bioactivity, such as declining body temperature and relieving inflammation. 18 It has an effectively antithermic and antibacterial role to infections caused by various virus and bacteria. 13, 18 It is likely that this mechanism is responsible for the clinical improvement that is observed in our study. More rigorous studies are needed to clarify the mechanisms of TCM in treating HFMD.
In summary, our study provides evidence that TCM, in the form of both Reduning and Xiyanping injections, can be safely used in the treatment of common HFMD. TCM can serve as a complementary medication to Western medicine, which accelerates the resolving symptoms of HFMD and should be highlighted in clinical settings. 
